Citations

Clear

1526 citation(s) found for "Sun, Yu".

Vagus Nerve and Stomach Synucleinopathy in Parkinson’s Disease, Incidental Lewy Body Disease, and Normal Elderly Subjects: Evidence Against the “Body-First” Hypothesis
Beach, Thomas G. , Sue, Lucia I., Shill, Holly A. , Driver‐Dunckley, Erika , Mehta, Shyamal H. , Intorcia, Anthony J., Glass, Michael J. , Walker, Jessica E. , Arce, Richard, Nelson, Courtney M. , Driver-Dunckley, Erika, Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Parkinson's Disease | June 15, 2021 | Volume: 11 | Issue: 4 | Pages: 1833-1843

10.3233/jpd-212733 | PMID 34151862 Get It

Background: Braak and others have proposed that Lewy-type α-synucleinopathy in Parkinson’s disease (PD) may arise from an exogenous pathogen that passes across the gastric mucosa and then is retrogradely transported up the vagus nerve to the medulla. Objective: We tested this hypothesis by immunohistochemically staining, with a method specific for p-serine 129 α-synuclein (pSyn), stomach and vagus nerve tissue from an autopsy series of 111 normal elderly subjects, 33 with incidental Lewy body disease (ILBD) and 53 with PD. Methods: Vagus nerve samples were taken adjacent to the carotid artery in the neck. Stomach samples were taken from the gastric body, midway along the greater curvature. Formalin-fixed paraffin-embedded sections were immunohistochemically stained for pSyn, shown to be highly specific and sensitive for α-synuclein pathology. Results: Median disease duration for the PD group was 13 years. In the vagus nerve none of the 111 normal subjects had pSyn in the vagus, while 12/26 ILBD (46%) and 32/36 PD (89%) subjects were pSyn-positive. In the stomach none of the 102 normal subjects had pSyn while 5/30 (17%) ILBD and 42/52 (81%) of PD subjects were pSyn-positive. Conclusion: As there was no pSyn in the vagus nerve or stomach of subjects without brain pSyn, these results support initiation of pSyn in the brain. The presence of pSyn in the vagus nerve and stomach of a subset of ILBD cases indicates that synucleinopathy within the peripheral nervous system may occur, within a subset of individuals, at preclinical stages of Lewy body disease.
Niclosamide blocks autophagy via lysosomal dysfunction (663.18)
Gao, Ying , Liang, Aiwen, Yin, Xiao‐Ming , Kang, Jeong Han , Liu, Peiqing , Li, Min

Mayo Clinic

The FASEB Journal | June 15, 2021 | Volume: 28 | Issue: S1 | Pages: No page available

10.1096/fasebj.28.1_supplement.663.18 Get It

Niclosamide is a salicylanilide derivative used as antihelminthic agent. Recently, Nic has been screened out as an autophagy modulator by us and other groups and was identified to be a structurally distinct mTORC1 signaling inhibitor. In this work, we measured the long‐lived protein degradation activity and found Niclosamide could inhibit the autophagic process. To elucidate the inhibition of Niclosamide on autophagy, we further tested the lysosomal activity using DQ‐BSA assay and measured protease activity such as Cathepsin B and Cathepsin D with fluorescent substrates. The lower degradation of DQ‐BSA and decreased protease activity after Niclosamide treatments indicated the impaired lysosome function. In addition, both LC‐II and P62 proteins accumulated significantly when treated by Niclosamide suggesting the late stage of autophagy was blocked. The increased pH of lysosome and release of Cathepsins from lysosome to cytosol demonstrated that Niclosamide might affect lysosome resulted from lysosomal membrane permeabilization. Collectively, we firstly disclosed Niclosamide not only inhibited mTORC1 activity but also, as other well‐known lysosome inhibitors, strongly blocked autophagy via lysosomal dysfunction. Grant Funding Source : Supported by Guandong Provincial Natural Science Foundation, China (S2013010015876)
Association Between Smoking and Molecular Subtypes of Colorectal Cancer
Wang, Xiaoliang , Amitay, Efrat L. , Harrison, Tabitha A. , Banbury, Barbara L. , Berndt, Sonja I. , Brenner, Hermann , Buchanan, Daniel D. , Campbell, Peter T. , Cao, Yin , Chang‐Claude, Jenny , Gallinger, Steven , Giannakis, Marios , Gunter, Marc J. , Nishihara, Reiko , Phipps, Amanda I. , Slattery, Martha L. , Song, Mingyang , Thibodeau, Steven, Guelpen, Bethany Van , Woods, Michael O. , Hoffmeister, Michael , Peters, Ulrike , Amitay, Efrat L , Chang-Claude, Jenny , Gunter, Marc J , Jenkins, Mark A , Moreno, Victor , Ogino, Shuji , Sakoda, Lori C , Schoen, Robert E , Song, Mingyang , Sun, Wei , Thibodeau, Steven N, Toland, Amanda Ewart , Woods, Michael O , Hoffmeister, Michael , Buchanan, Daniel D , Campbell, Peter T , Cao, Yin , Harrison, Tabitha A , Van Guelpen, Bethany , Brenner, Hermann , Wang, Xiaoliang , Chan, Andrew T. , Giles, Graham G. , Hopper, John L. , Jenkins, Mark A. , Lin, Yi , Moreno, Vı́ctor , Newcomb, Polly A. , Sakoda, Lori C. , Schoen, Robert E. , Sun, Wei , Hsu, Li

Mayo Clinic

JNCI Cancer Spectrum | June 13, 2021 | Volume: 5 | Issue: 4 | Pages: No page available

10.1093/jncics/pkab056 | PMID 34377935 Get It

Abstract Background Smoking is associated with colorectal cancer (CRC) risk. Previous studies suggested this association may be restricted to certain molecular subtypes of CRC, but large-scale comprehensive analysis is lacking. Methods A total of 9789 CRC cases and 11 231 controls of European ancestry from 11 observational studies were included. We harmonized smoking variables across studies and derived sex study–specific quartiles of pack-years of smoking for analysis. Four somatic colorectal tumor markers were assessed individually and in combination, including BRAF mutation, KRAS mutation, CpG island methylator phenotype (CIMP), and microsatellite instability (MSI) status. A multinomial logistic regression analysis was used to assess the association between smoking and risk of CRC subtypes by molecular characteristics, adjusting for age, sex, and study. All statistical tests were 2-sided and adjusted for Bonferroni correction. Results Heavier smoking was associated with higher risk of CRC overall and stratified by individual markers (Ptrend < .001). The associations differed statistically significantly between all molecular subtypes, which was the most statistically significant for CIMP and BRAF. Compared with never-smokers, smokers in the fourth quartile of pack-years had a 90% higher risk of CIMP-positive CRC (odds ratio = 1.90, 95% confidence interval = 1.60 to 2.26) but only 35% higher risk for CIMP-negative CRC (odds ratio = 1.35, 95% confidence interval = 1.22 to 1.49; Pdifference = 2.1 x 10-6). The association was also stronger in tumors that were CIMP positive, MSI high, or KRAS wild type when combined (Pdifference < .001). Conclusion Smoking was associated with differential risk of CRC subtypes defined by molecular characteristics. Heavier smokers had particularly higher risk of CRC subtypes that were CIMP positive and MSI high in combination, suggesting that smoking may be involved in the development of colorectal tumors via the serrated pathway.
Discovery of Small Molecule Modulators targeting Secretin Receptors
Dengler, Daniela G. , Pollari, Sirkku , Sun, Qing , Ardecky, Robert, Sergienko, Eduard , Harikumar, Kaleeckal G. , Miller, Laurence J.

Mayo Clinic

The FASEB Journal | June 10, 2021 | Volume: 35 | Issue: S1 | Pages: No page available

10.1096/fasebj.2021.35.s1.03368 Get It

Class B G protein‐coupled receptors (GPCRs) are a highly important group of therapeutic targets with strong physiologic implications in cardiovascular, metabolic, or gastrointestinal systems. Endogenously activated by moderate‐length peptide hormones, class B GPCRs entertain a complex binding mechanism to induce stimulatory signaling processes. The secretin receptor (SCTR) is a prototypical member of this receptor family, having clinical relevance in multiple diseases including heart failure, digestive disorders, diabetes and obesity. [1‐4] However, its endogenous ligand secretin and peptide‐based analogs are the only ligands known to interact with SCTRs, likely due to challenges in class B GPCR drug discovery [5]. To find orally available therapeutic leads targeting this “undruggable” receptor, we focused on identifying positive allosteric modulators (PAMs), which act via structurally distinct binding pockets and potentiate hormonal signaling of native agonists. Thus, we developed a testing funnel tailored to discover SCTR small molecule modulators. After screening a 12,000‐compound library with a unique primary assay that used a mixture of stimulators, we identified three structurally related scaffolds (A‐C) enhancing peptidic SCTR activation [5]. Applying a comprehensive toolbox with binding and functional assays, we studied structure‐activity relationships of a well‐considered set of commercially available analogs incorporating these three scaffolds. Our investigations afforded an optimized analog B2, which showed substantial positive cooperativity to low‐potent peptide agonists and significantly decelerated secretin dissociation. Due to the innate electrophilicity of scaffold set A, we recognized a structural similarity to PAMs acting on glucagon‐like peptide‐1 receptor (GLP‐1R), a prominent member of class B GPCR family. We further demonstrated that a subset of SCTR PAMs was able to augment not only SCTR signaling but also GLP‐1R functions. A recent study described that dual activation of SCTRs and GLP‐1Rs was benefiting glucose homeostasis and appetite regulation while avoiding proliferative effects on pancreas mass [6]. Determining cooperativity between PAMs and selected orthosteric peptides, we established distinct selectivity and probe dependency profiles. To decipher reversible and covalent mechanisms‐of‐action as well as potential binding sites of novel PAMs, we conducted glutathione reactivity, cAMP‐washout and receptor mutational studies. [7] To conclude, we discovered a unique class of SCTR modulators providing useful pharmacologic tools to study SCTR‐ or GLP‐1R‐specific activation pathways and explore novel allosteric binding sites with potential to instigate the development of first‐in‐class therapeutics for treating comorbid conditions obesity and diabetes. [7] References [1] Annu Rev Pharmacol Toxicol, 2020 , 60 , 89‐107; [2] Trends in Biochemical Sciences, 2017 , 12 , 946‐960; [3] Experimental Physiology, 2013 , 5 , 973‐987; [4] Current Neuropharmacology, 2007 , 3 , 168‐179; [5] SLAS Discovery, 2021 , 26 , 1‐16; [6] Journal of Peptide Science, 2017 , 12 , 845‐854; [7] submitted to Biochemical Pharmacology 2021 .
Abstract NT-101: QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS
Cloven, Noelle, Hendrickson, Andrea E. Wahner , DiSilvestro, Paul , Cristea, Mihaela , Chan, John K. , Li, Yong , Sun, Kaiming, Matulonis, Ursula A. , Monk, Bradley J. , Moore, Kathleen N. , Secord, Angeles Alvarez , Geller, Melissa Ann , Miller, David S. , Fleming, Gini F. , Azodi, Masoud , Oza, Amit M. , Berek, Jonathan S. , Sun, Kaiming , Luptakova, Katarina

Mayo Clinic

Clinical Cancer Research | June 10, 2021 | Volume: 25 | Issue: 22_Supplement | Pages: NT-101-NT-101

10.1158/1557-3265.ovcasymp18-nt-101 Get It

Abstract BACKGROUND: Patients with ROC have limited treatment options in later lines of therapy, as many become platinum-resistant or -ineligible. Poly(ADP-ribose) polymerase inhibitor (PARPi) treatment is one option, however these agents are currently not approved for BRCAwt patients in the treatment setting. Niraparib, a PARPi, has demonstrated increased progression-free survival vs placebo as maintenance therapy for platinum-responsive ROC. Niraparib was effective regardless of BRCAmut or homologous recombination deficiency (HRD) status, although an increased treatment effect was observed in the HRDpos population. QUADRA (NCT02354586) evaluated niraparib treatment in heavily pretreated ROC patients, regardless of BRCAmut or HRD status, platinum sensitivity, or prior PARPi use. METHODS: Eligible patients had grade 2-3 serous ROC, ≥3 prior chemotherapy lines, and measurable disease. Patients were evaluated for BRCAmut and HRD status (MyChoice HRD Test). Patients received niraparib 300 mg once daily until progression; dose could be lowered to 200 mg or 100 mg due to treatment-emergent adverse events (TEAEs). The primary endpoint was objective response rate (ORR) per RECIST v1.1 in patients treated in 4th or 5th line who were HRDpos, platinum sensitive, and PARPi naïve. RESULTS: 463 patients were treated. Of these, 161 were platinum refractory, 151 platinum resistant, and 120 platinum sensitive to their last line of platinum therapy. Of note, 83 patients were primary platinum resistant or refractory (42 and 41, respectively). Median number of prior lines of therapy was 4 (range 2-16), and 27% of patients were treated in 6th or later line. 100% of patients received prior platinum, 99.6% received prior taxane, 81% received prior doxorubicin, 63% received prior bevacizumab, and 59% received prior gemcitabine. In the primary efficacy population (N=45), ORR was 29% (95% CI: 16-44, P=0.0003), disease control rate (DCR) was 71% (95% CI: 56-84), and duration of response (DOR) was 9.2 months (95% CI: 5.9-NE); overall survival (OS) was not reached (95% CI: 18.5-NE). The efficacy outcomes in all 456 patients with measurable disease at baseline treated in 4th or later line demonstrated a DCR of 49% with 2 complete responses (CR), 36 partial responses (PR), and 187 patients with stable disease (SD). The responses were durable with a median DOR of 9.4 months, a clinical benefit rate (CR+PR+SD) at 16 weeks of 29%, and median OS of 17.2 months (95% CI: 14.9-19.8) among all patients treated in 4th or later line. 266 (57.5%) patients had grade ≥3 treatment-related TEAEs. Grade ≥3 thrombocytopenia event (thrombocytopenia or decreased platelet count) by dose at onset of the event was 27.5% at 300 mg, 4.7% at 200 mg, and 2.7% at 100 mg. The other most common grade ≥3 TEAEs were anemia (26.3%) and neutropenia (8.2%). Hematologic TEAEs were most frequent in the first month and decreased in frequency and severity after dose reduction during months 2-3. CONCLUSIONS: Niraparib demonstrated durable anticancer activity in this heavily treated (≥3 lines) ROC population, including platinum-resistant or BRCAwt patients. Toxicities were consistent with previous niraparib studies. DISCLOSURE Funded by TESARO, Inc. Citation Format: Kathleen Moore, Angeles Secord, Melissa Geller, David Miller, Noelle Cloven, Gini Fleming, Andrea E. Wahner Hendrickson, Masoud Azodi, Paul Disilvestro, Amit Oza, Mihaela Cristea, Jonathan S. Berek, John Chan, Yong Li, Kaiming Sun, Katarina Luptakova, Ursula A. Matulonis, Bradley J. Monk. QUADRA: A PHASE 2, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE SINGLE-AGENT NIRAPARIB TREATMENT IN PATIENTS WITH RELAPSED OVARIAN CANCER (ROC) WHO HAVE RECEIVED ≥3 PRIOR CHEMOTHERAPY REGIMENS [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr NT-101.
Transcriptomic Analysis Reveals the MicroRNAs Responsible for Liver Regeneration Associated With Mortality in Alcohol‐Associated Hepatitis
Zhang, Ting , Kusumanchi, Praveen , Tang, Qing , Sun, Zhaoli , Radaeva, Svetlana , Peiffer, Brandon , Shah, Vijay H. , Kamath, Patrick S. , Gores, G. J., Chalasani, Naga , Jiang, Yanchao, Ma, Jing , Liangpunsakul, Suthat , Shah, Vijay H , Kamath, Patrick, Gores, Greg J, Chalasani, Naga , Peiffer, Brandon , Yang, Zhihong , Sanyal, Arun J. , Huda, Nazmul

Mayo Clinic

Hepatology | June 7, 2021 | Volume: 74 | Issue: 5 | Pages: 2436-2451

10.1002/hep.31994 | PMID 34096637 Get It

Background and Aims We conducted a comprehensive serum transcriptomic analysis to explore the roles of microRNAs (miRNAs) in alcohol‐associated hepatitis (AH) pathogenesis and their prognostic significance. Approach and Results Serum miRNA profiling was performed in 15 controls, 20 heavy drinkers without liver disease, and 65 patients with AH and compared to publicly available hepatic miRNA profiling in AH patients. Among the top 26 miRNAs, expression of miR‐30b‐5p, miR‐20a‐5p, miR‐146a‐5p, and miR‐26b‐5p were significantly reduced in both serum and liver of AH patients. Pathway analysis of the potential targets of these miRNAs uncovered the genes related to DNA synthesis and cell‐cycle progression pathways, including ribonucleotide reductase regulatory subunit M2 (RRM2), cyclin D1 (CCND1), cyclin D2 (CCND2), MYC proto‐oncogene (MYC), and phorbol‐12‐myristate‐13‐acetate‐induced protein 1 (PMAIP1). We found a significant increase in the protein expression of RRM2, CCND1, and CCND2, but not MYC and PMAIP1, in AH patients who underwent liver transplantation; miR‐26b‐5p and miR‐30b‐5p inhibited the 3′‐UTR (untranslated region) luciferase activity of RRM2 and CCND2, and miR‐20a‐5p reduced the 3′‐UTR luciferase activity of CCND1 and CCND2. During a median follow‐up of 346 days, 21% of AH patients died; these patients had higher body mass index (BMI), Model for End‐Stage Liver Disease (MELD), and serum miR‐30b‐5p, miR‐20a‐5p, miR‐146a‐5p, and miR‐26b‐5p than those who survived. Cox regression analysis showed that BMI, MELD score, miR‐20a‐5p, miR‐146a‐5p, and miR‐26b‐5p predicted mortality. Conclusions Patients with AH attempt to deal with hepatocyte injury by down‐regulating specific miRNAs and up‐regulating genes responsible for DNA synthesis and cell‐cycle progression. Higher expression of these miRNAs, suggestive of a diminished capacity in liver regeneration, predicts short‐term mortality in AH patients.
A novel ferroptosis phenotype‐related clinical‐molecular prognostic signature for hepatocellular carcinoma
Deng, Tuo , Hu, Bingren, Chen, Jin , Tong, Yifan , Zhao, Jungang , Shi, Zhehao , Deng, Liming , Chen, Gang , Wang, Yi , Chen, Gang , Wang, Yi , Zhang, Tan , Sun, Zhifu

Mayo Clinic

Journal of Cellular and Molecular Medicine | June 4, 2021 | Volume: 25 | Issue: 14 | Pages: 6618-6633

10.1111/jcmm.16666 | PMID 34085405 Get It

AbstractFerroptosis is a newly identified cell death mechanism and potential biomarker for hepatocellular carcinoma (HCC) therapy; however, its clinical relevance and underlying mechanism remain unclear. In this study, transcriptome and methylome data from 374 HCC cases were investigated for 41 ferroptosis‐related genes to identify ferroptosis activity‐associated subtypes. These subtypes were further investigated for associations with clinical and pathological variables, gene mutation landscapes, deregulated pathways and tumour microenvironmental immunity. A gene expression signature and predictive model were developed and validated using an additional 232 HCC cases from another independent cohort. Two distinct ferroptosis phenotypes (Ferroptosis‐H and Ferroptosis‐L) were identified according to ferroptosis gene expression and methylation in the patients with HCC. Patients with the Ferroptosis‐H had worse overall and disease‐specific survival, and the molecular subtypes were significantly associated with different clinical characteristics, mRNA expression patterns, tumour mutation profiles and microenvironmental immune status. Furthermore, a 15‐gene ferroptosis‐related prognostic model (FPM) for HCC was developed and validated which demonstrated accurate risk stratification ability. A nomogram included the FPM risk score, ECOG PS and hepatitis B status was developed for eventual clinical translation. Our results suggest that HCC subtypes defined by ferroptosis gene expression and methylation may be used to stratify patients for clinical decision‐making.
Comprehensive Analysis of SFRP Family Members Prognostic Value and Immune Infiltration in Gastric Cancer
Liu, Dehua , Sun, Chenyu , Kim, Na Hyun , Bhan, Chandur , Tuason, John Pocholo W., Chen, Yue , Huang, Yuting , Cheng, Ce , Zhou, Qin , Zhang, Kaiguang , Kim, Nahyun , Huang, Yuting , Zhang, Kaiguang , Sun, Chenyu , Ma, Shaodi

Mayo Clinic

Life | June 3, 2021 | Volume: 11 | Issue: 6 | Pages: 522

10.3390/life11060522 | PMID 34205081 Get It

Gastric cancer (GC) is the fifth most common cancer globally. Secreted frizzled-related proteins (SFRP) are important elements associated with the Wnt signaling pathway, and its dysregulated expression is found in multiple cancers. However, the function of distinct SFRPs in GC remains poorly understood. We investigated the differential expression, prognostic value, and immune cell infiltration of SFRPs in gastric cancer patients from the Oncomine, Gene Expression Profiling Interactive Analysis (GEPIA), UALCAN, Kaplan–Meier plotter, cBioPortal, STRING, Gene-MANIA, DAVID, MethSurv, and TIMER databases. We found that the expression levels of SFRP2 and SFRP4 were significantly increased in GC tissues, whereas the SFRP1 and SFRP5 expressions were reduced. SFRP1, SFRP2, and SFRP5 were significantly correlated with the clinical cancer stage in GC patients. Higher expression of SFRPs was associated with short overall survival (OS) in GC patients. Besides, high SFRPs methylation showed favorable OS in GC patients. The functions of SFRPs were primarily related to the Wnt signaling pathway, immune system development, and basal cell carcinoma. The expression of SFRPs was strongly correlated with immune infiltrating cells, including CD4+ T cells and macrophages in GC. Our study indicated that SFRPs could be potential targets of precision therapy and prognostic biomarkers for the survival of GC patients.
Influencing Factors on the Oncuria™ Urinalysis Assay: An Experimental Model
Murakami, Kaoru , Pagano, Ian , Chen, Runpu , Goodison, Steve , Rosser, Charles J. , Furuya, Hideki , Rosser, Charles J , Furuya, Hideki , Sun, Yijun

Mayo Clinic

Diagnostics | June 3, 2021 | Volume: 11 | Issue: 6 | Pages: 1023

10.3390/diagnostics11061023 | PMID 34204951 Get It

Background: The Oncuria™ urine test for the detection of bladder cancer measures a multiplex protein signature. In this study, we investigated the influence of urinary cellularity, protein, and hematuria on the performance of the Oncuria™ test in an ex vivo experimental model. Materials and Methods: Pooled urine from healthy subjects was spiked with cultured benign (UROtsa) or malignant cells (T24), cellular proteins, or whole blood. The resulting samples were analyzed using the Oncuria™ test following the manufacturer’s instructions. Results: Urine samples obtained from healthy subjects were negative for bladder cancer by Oncuria™ test criteria. The majority of the manipulated conditions did not result in a false-positive test. The addition of whole blood (high concentration) did result in a false-positive result, but this was abrogated by sample centrifugation prior to analysis. The addition of cellular proteins (high concentration) resulted in a positive Oncuria™ test, and this was unaffected by pre-analysis sample centrifugation. Conclusions: The Oncuria™ multiplex test performed well in the ex vivo experimental model and shows promise for clinical application. The identification of patients who require additional clinical evaluation could reduce the need to subject patients who do not have bladder cancer to frequent, uncomfortable and expensive cystoscopic examinations, thus benefiting both patients and the healthcare system.